Standardized Withaferin A (SWA)

Phase 2

Standardized Withaferin A (SWA) is one of 5 therapeutic programs targeting Hematological Malignancy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Hematological MalignancyRecruiting

Hematological MalignancyPhase 2

Recruiting

Competition

Competitive Landscape

6 competitors in Hematological Malignancy

#DrugCompanyPhaseTrials

Fludara

Sanofi

Preclinical

1 2

Cytoxan

BBaxter Healthcare Corporation

Preclinical

2 3

Standardized Withaferin A (SWA)

TTata Memorial Centre

Phase 2

1 4

Anti-Human Thymoglobulin

SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 1

1 5

CTA101

TThe First Affiliated Hospital with Nanjing Medical University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Hematological Malignancy

NCT07708987

Clinical

Trials by Indication[1]

Hematological Malignancy1 trial

A Phase II Clinical Trial of Standardized Withaferin-A for the Treatment of Steroid Refractory Acute Graft Versus Host Disease

Recruiting·TTata Memorial Centre·Phase 2·NCT07708987·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Standardized Withaferin A (SWA). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Standardized Withaferin A (SWA). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Tata Memorial Centre company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: TTata Memorial Centre

Standardized Withaferin A (SWA)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Hematological Malignancy1 trial

References

Drug Info

Quick Facts

Related News